Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease of the lungs. It is characterized by pulmonary and extrapulmonary comorbidities. So far, little is known as regards the prevalence of cardiovascular comorbidities in IPF patients. This study aims to...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-01-01
|
| Series: | The Egyptian Journal of Bronchology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43168-025-00364-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585977517834240 |
|---|---|
| author | Mohamed F. AbdelGhany Waleed GamalEldin Khaleel Asmaa Omar Ahmed Ahmad BaheyElden Ahmed Lamees M. Bakkar |
| author_facet | Mohamed F. AbdelGhany Waleed GamalEldin Khaleel Asmaa Omar Ahmed Ahmad BaheyElden Ahmed Lamees M. Bakkar |
| author_sort | Mohamed F. AbdelGhany |
| collection | DOAJ |
| description | Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease of the lungs. It is characterized by pulmonary and extrapulmonary comorbidities. So far, little is known as regards the prevalence of cardiovascular comorbidities in IPF patients. This study aims to investigate the prevalence of cardiovascular comorbidities in patients with IPF and correlate it with different radiological and laboratory indices of disease severity. Methods This prospective case–control study was performed on 134 IPF patients above 18 years. Diagnosis of IPF was based on diagnostic radiologic criteria addressed by ATS guidelines. Patients were recruited from the Pulmonology Department, Assiut University Hospitals, from June 2023 to June 2024. Cardiac comorbidities were assessed by ECG and echocardiography. All patients had C-reactive protein (CRP), Krebs von den Lungen-6 (KL-6), and lipid profile including cholesterol level, triglyceride level, HDL-cholesterol level, and LDL-cholesterol level measured. Patients were divided into two groups: IPF patients with cardiovascular comorbidities and IPF patients without cardiovascular comorbidities. Comparison between both groups as regards clinical, radiological, and laboratory criteria was carried out. Results The studied group consists predominantly of females (65%). Sixty out of the 134 documented IPF patients had cardiovascular comorbidities (44.7%), cardiomyopathy (mean ± SD: 43.63 ± 10.56), pulmonary hypertension (mean ± SD: 41.67 ± 15.32), ECG-ischemic changes (40.0%), and atrial fibrillation (13.3%). IPF patients with cardiovascular comorbidities vs. patients without had higher radiological HRCT total fibrosis score TFS (P value < 0.001). As regards laboratory serum biomarkers, the group with comorbidities showed significantly higher CRP, KL-6, cholesterol level, triglyceride level, and LDL-cholesterol level (P value < 0.001). Box plot analysis demonstrated significantly higher KL-6 serum level among IPF patients with cardiovascular comorbidities. Sensitivity 90.0%, specificity 94.6%, and accuracy 92.5% were associated with a cutoff value of KL-6 ≥ 299 for prediction of associated cardiovascular comorbidities among the studied IPF group. Conclusions Dyslipidemia and cardiovascular comorbidities were detected in a large group of IPF patients. These comorbidities were associated with a high HRCT TFS score. High serum levels of CRP and KL-6 were predictors of associated cardiovascular comorbidities in IPF. Trial registration ClinicalTrials.gov. NCT06539962. |
| format | Article |
| id | doaj-art-322159133c814528b2943b35060065c8 |
| institution | Kabale University |
| issn | 2314-8551 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Bronchology |
| spelling | doaj-art-322159133c814528b2943b35060065c82025-01-26T12:19:03ZengSpringerOpenThe Egyptian Journal of Bronchology2314-85512025-01-011911710.1186/s43168-025-00364-8Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammationMohamed F. AbdelGhany0Waleed GamalEldin Khaleel1Asmaa Omar Ahmed2Ahmad BaheyElden Ahmed3Lamees M. Bakkar4Chest Department, Faculty of Medicine, Assiut UniversityChest Department, Faculty of Medicine, Assiut UniversityClinical Pathology Department, Faculty of Medicine, Assiut UniversityCritical Care Unit, Internal Medicine Department, Faculty of Medicine, Assiut UniversityChest Department, Faculty of Medicine, Assiut UniversityAbstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease of the lungs. It is characterized by pulmonary and extrapulmonary comorbidities. So far, little is known as regards the prevalence of cardiovascular comorbidities in IPF patients. This study aims to investigate the prevalence of cardiovascular comorbidities in patients with IPF and correlate it with different radiological and laboratory indices of disease severity. Methods This prospective case–control study was performed on 134 IPF patients above 18 years. Diagnosis of IPF was based on diagnostic radiologic criteria addressed by ATS guidelines. Patients were recruited from the Pulmonology Department, Assiut University Hospitals, from June 2023 to June 2024. Cardiac comorbidities were assessed by ECG and echocardiography. All patients had C-reactive protein (CRP), Krebs von den Lungen-6 (KL-6), and lipid profile including cholesterol level, triglyceride level, HDL-cholesterol level, and LDL-cholesterol level measured. Patients were divided into two groups: IPF patients with cardiovascular comorbidities and IPF patients without cardiovascular comorbidities. Comparison between both groups as regards clinical, radiological, and laboratory criteria was carried out. Results The studied group consists predominantly of females (65%). Sixty out of the 134 documented IPF patients had cardiovascular comorbidities (44.7%), cardiomyopathy (mean ± SD: 43.63 ± 10.56), pulmonary hypertension (mean ± SD: 41.67 ± 15.32), ECG-ischemic changes (40.0%), and atrial fibrillation (13.3%). IPF patients with cardiovascular comorbidities vs. patients without had higher radiological HRCT total fibrosis score TFS (P value < 0.001). As regards laboratory serum biomarkers, the group with comorbidities showed significantly higher CRP, KL-6, cholesterol level, triglyceride level, and LDL-cholesterol level (P value < 0.001). Box plot analysis demonstrated significantly higher KL-6 serum level among IPF patients with cardiovascular comorbidities. Sensitivity 90.0%, specificity 94.6%, and accuracy 92.5% were associated with a cutoff value of KL-6 ≥ 299 for prediction of associated cardiovascular comorbidities among the studied IPF group. Conclusions Dyslipidemia and cardiovascular comorbidities were detected in a large group of IPF patients. These comorbidities were associated with a high HRCT TFS score. High serum levels of CRP and KL-6 were predictors of associated cardiovascular comorbidities in IPF. Trial registration ClinicalTrials.gov. NCT06539962.https://doi.org/10.1186/s43168-025-00364-8Idiopathic pulmonary fibrosisKL-6Ischemic cardiomyopathyAtrial fibrillation |
| spellingShingle | Mohamed F. AbdelGhany Waleed GamalEldin Khaleel Asmaa Omar Ahmed Ahmad BaheyElden Ahmed Lamees M. Bakkar Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation The Egyptian Journal of Bronchology Idiopathic pulmonary fibrosis KL-6 Ischemic cardiomyopathy Atrial fibrillation |
| title | Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation |
| title_full | Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation |
| title_fullStr | Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation |
| title_full_unstemmed | Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation |
| title_short | Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation |
| title_sort | idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease potential role of kl 6 and systemic inflammation |
| topic | Idiopathic pulmonary fibrosis KL-6 Ischemic cardiomyopathy Atrial fibrillation |
| url | https://doi.org/10.1186/s43168-025-00364-8 |
| work_keys_str_mv | AT mohamedfabdelghany idiopathicpulmonaryfibrosisisariskfactorforcardiovasculardiseasepotentialroleofkl6andsystemicinflammation AT waleedgamaleldinkhaleel idiopathicpulmonaryfibrosisisariskfactorforcardiovasculardiseasepotentialroleofkl6andsystemicinflammation AT asmaaomarahmed idiopathicpulmonaryfibrosisisariskfactorforcardiovasculardiseasepotentialroleofkl6andsystemicinflammation AT ahmadbaheyeldenahmed idiopathicpulmonaryfibrosisisariskfactorforcardiovasculardiseasepotentialroleofkl6andsystemicinflammation AT lameesmbakkar idiopathicpulmonaryfibrosisisariskfactorforcardiovasculardiseasepotentialroleofkl6andsystemicinflammation |